期刊
MEDICINA-LITHUANIA
卷 55, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/medicina55100707
关键词
Sorafenib; hepatocellular carcinoma; prognostic factors; predictive factors
资金
- Apulian Regional Project Medicina di Pecisione
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据